TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from SAI Life Sciences Ltd. ( (IN:SAILIFE) ).
Sai Life Sciences Limited reported a significant 77% year-on-year revenue growth for the first quarter of Fiscal Year 2026, driven by strong performance in its CDMO segment. The company achieved a revenue of ₹496 crore, an EBITDA of ₹125 crore, and a net profit of ₹60 crore. The company expanded its manufacturing capacity and research capabilities, inaugurating new facilities and investing in infrastructure to support complex drug development. These developments reflect the company’s strategic focus on enhancing its service offerings and strengthening its position in the global pharmaceutical market.
More about SAI Life Sciences Ltd.
Sai Life Sciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) focused on innovation. The company operates in the pharmaceutical industry, providing services in drug discovery, development, and commercial manufacturing, with a strong emphasis on complex peptides and emerging modalities.
Average Trading Volume: 366,016
Technical Sentiment Signal: Strong Buy
Current Market Cap: 165.6B INR
Learn more about SAILIFE stock on TipRanks’ Stock Analysis page.